Clinical trialNCT05687136RecruitingPhase 1Interventional

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors

SponsorNational Cancer Institute (NCI)Enrollment66Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I trial tests the safety, side effects and best dose of peposertib (M3814) in combination with tuvusertib (M1774) in treating patients with solid tumors that have spread to other places in the body (advanced). Peposertib and tuvusertib stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Gregory M Cote
Dana-Farber - Harvard Cancer Center LAO
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland, United States
A P. Chen
Recruiting
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Active, not recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Candace L. Haddox
Recruiting
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
Gregory M. Cote
Recruiting
Nyu Langone Hospital - Long Island
Mineola, New York, United States
Nancy Chan
Recruiting
Laura and Isaac Perlmutter Cancer Center at Nyu Langone
New York, New York, United States
Nancy Chan
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

NedisertibTuvusertib

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 7 Jun 2024
Primary completion: 31 Aug 2027
Completion: 31 Aug 2027
Last update posted: 21 Aug 2026
Registered enrollment: 66
Registry id: NCT05687136

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.